- Home
- SSSS vs CRBP Comparison
SSSS vs CRBP Comparison
Compare SSSS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- CRBP
- Stock Information
- Founded
- SSSS 2010
- CRBP 2009
- Country
- SSSS United States
- CRBP United States
- Employees
- SSSS N/A
- CRBP N/A
- Industry
- SSSS Finance: Consumer Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- CRBP Health Care
- Exchange
- SSSS Nasdaq
- CRBP Nasdaq
- Market Cap
- SSSS 138.2M
- CRBP 114.8M
- IPO Year
- SSSS N/A
- CRBP N/A
- Fundamental
- Price
- SSSS $9.27
- CRBP $9.50
- Analyst Decision
- SSSS Strong Buy
- CRBP Strong Buy
- Analyst Count
- SSSS 4
- CRBP 10
- Target Price
- SSSS $9.50
- CRBP $53.22
- AVG Volume (30 Days)
- SSSS 253.2K
- CRBP 91.8K
- Earning Date
- SSSS 11-06-2025
- CRBP 11-06-2025
- Dividend Yield
- SSSS 10.75%
- CRBP N/A
- EPS Growth
- SSSS N/A
- CRBP N/A
- EPS
- SSSS 2.22
- CRBP N/A
- Revenue
- SSSS $2,784,381.00
- CRBP N/A
- Revenue This Year
- SSSS $6.95
- CRBP N/A
- Revenue Next Year
- SSSS N/A
- CRBP $220.04
- P/E Ratio
- SSSS $4.19
- CRBP N/A
- Revenue Growth
- SSSS N/A
- CRBP N/A
- 52 Week Low
- SSSS $3.75
- CRBP $4.64
- 52 Week High
- SSSS $9.34
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- SSSS 72.57
- CRBP 49.85
- Support Level
- SSSS $8.63
- CRBP $9.42
- Resistance Level
- SSSS $8.75
- CRBP $9.73
- Average True Range (ATR)
- SSSS 0.15
- CRBP 0.51
- MACD
- SSSS 0.03
- CRBP -0.08
- Stochastic Oscillator
- SSSS 91.78
- CRBP 15.33
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.